FDA approves olaparib for patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC)

Approval was based on phase III PROfound trial, which showed a statistically-significant improvement in primary endpoint of radiographic progression-free survival with olaparib vs. enzalutamide or abiraterone (improved by 7.4 vs. 3.6 months).

Source:

Biospace Inc.